HC Wainwright & Co.：重申AEterna Zentaris(AEZS.US)買入評級, 目標價28.00美元。 依特鈉（AEZS.US）公司簡介：苩erna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and devel...
HC Wainwright & Co.：重申AEterna Zentaris(AEZS.US)買入評級, 目標價28.00美元。
依特鈉（AEZS.US）公司簡介：苩erna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.
以上內容由證券之星根據公開信息整理，與本站立場無關。證券之星力求但不保證該信息（包括但不限于文字、視頻、音頻、數據及圖表）全部或者部分內容的的準確性、完整性、有效性、及時性等，如存在問題請聯系我們。本文為數據整理，不對您構成任何投資建議，投資有風險，請謹慎決策。
jay
